Pharma social media marketing: what a post, a comment and a creator each have to get right

Pharma social media marketing works when each account knows what it is allowed to say. In the United States, a post that names a prescription drug and what it does is advertising, so it needs risk information with fair balance, just like a print ad. A post that names the drug without saying what it treats can be a reminder post, which FDA rules allow except for drugs with a boxed warning. Comments can contain adverse event reports that the company must review. So a working plan separates corporate, disease awareness and branded accounts, writes the review and monitoring process before the first post, and treats paid creators as the brand's own voice. The rules quoted here were read in the eCFR and the Federal Register on 21 October 2026. This is a marketing guide, and your regulatory team has the final word.

For the wider channel plan, including search, email and HCP channels, see our guide to digital marketing for pharmaceutical companies. This page goes deep on social alone.

Three kinds of account, three different rulebooks

Account	What it talks about	What it must avoid
Corporate	The company, its people, research news, careers, community work	Turning into product promotion through the back door
Disease awareness	A condition, its symptoms and when to see a doctor, with no product named	Linking to or hinting at a branded product in a way that makes it promotion
Branded product	One medicine, its approved use and its risks	Benefit claims without risk information, and anything outside the approved labeling

Keep these apart in practice, not only on paper. Separate handles, separate content calendars and a written rule on what each one may link to make reviews faster and mistakes rarer.

What a branded post has to carry

Under 21 CFR 202.1(e)(1), advertisements for a prescription drug must include a true brief summary of side effects, contraindications and effectiveness, with fair balance between risk and benefit. A branded social post that says what the drug does is held to that standard.

Reminder posts

The same regulation exempts reminder advertisements, which "call attention to the name of the drug product but do not include indications or dosage recommendations" (202.1(e)(2)(i)). A post with the brand name and nothing about what it treats can fit that shape. There is a firm limit: reminder advertisements, other than price-only ones, "are not permitted for a prescription drug product whose labeling contains a boxed warning relating to a serious hazard." Check the label before planning any reminder content.

Short formats with little space

In June 2014 FDA published a draft guidance on social media platforms with character space limits. It describes how firms that choose to present benefit information should present both benefit and risk information within those limited formats. It is still a draft, so treat it as FDA's stated thinking. The practical rule for a content team is simple: if the risk information cannot sit properly beside the benefit in that format, the benefit claim does not belong in that format.

Comments, messages and adverse events

Social media invites replies, and some replies describe side effects. Under 21 CFR 314.80(b), an applicant "must promptly review all adverse drug experience information obtained or otherwise received by the applicant from any source." A comment or direct message can be that information. Before a branded or disease awareness account opens comments, agree on these points with the safety team:

• Who monitors each account, on which days and how quickly.
• What counts as a possible adverse event and how it reaches pharmacovigilance.
• A standard public reply that moves the person to a private channel or a medical information line.
• Whether comments are open at all on each account. Many brands close comments on branded posts and keep them open on corporate ones.

Correcting misinformation about your product

Patients share wrong information about medicines on social media every day. In July 2024 FDA published a revised draft guidance, "Addressing Misinformation About Medical Devices and Prescription Drugs: Questions and Answers." It revises and replaces the 2014 draft on correcting independent third-party misinformation. It describes "tailored responsive communications", which are a firm's voluntary, internet-based replies to specific misinformation about its own product created by an independent third party, and "general medical product communications". FDA's notice says the revised draft "is not final nor is it in effect at this time." If you plan to correct misinformation, build the process from that document with your regulatory team.

Paid creators and patient ambassadors

Patients and doctors who share their own experience can be powerful voices, and they bring two sets of rules with them.

• The FTC's Endorsement Guides (16 CFR 255.5) say a material connection the audience would not expect, such as payment or free product, must be disclosed clearly and conspicuously. On social media, the disclosure "should be unavoidable" (255.0(f)).
• FDA rules still apply. 21 CFR 202.1(l)(2) treats material disseminated "by or on behalf of" the manufacturer as labeling. When a company pays for a post about its drug, plan for that post to need the same review, fair balance and risk information as the brand's own posts.

Write the approved claims, the required risk text and the disclosure into the creator contract, review each post before it goes live, and keep a copy of what was published.

Submissions and records

21 CFR 314.81(b)(3)(i) requires specimens of promotional labeling and advertising to be submitted at the time of initial dissemination or publication, using Form FDA-2253. In January 2014 FDA also issued a draft guidance on fulfilling postmarketing submission requirements for interactive promotional media, which covers how firms submit content on sites they control or influence. Keep an archive of every promotional post, including the creative, the caption, the date and the approval record.

Pharma social media campaigns that tend to work

• Disease awareness with real people. Patients describing life with a condition, with consent and with no product named, can reach people who have never been diagnosed.
• Corporate science stories. Researchers explaining their work build trust and help hiring.
• HCP education on professional networks. Content aimed at prescribers often sits better on LinkedIn than on consumer platforms.
• Support programme awareness. Posts about savings cards or nurse support lines help people who already have a prescription.

Every platform also has its own health and medicines ad policy. Read the current version for each one before you plan paid posts, because the rules differ between platforms and countries. If you are choosing outside help, our comparison of health care marketing agencies explains how the review chain changes which kind of agency fits.

Questions about pharma social media marketing

Can pharmaceutical companies advertise on social media?

Yes, in the US, within FDA's advertising rules and each platform's own health ad policy. A branded post that names benefits needs risk information with fair balance, just like other drug advertising.

What is a reminder post in pharma social media?

A post that names the drug but does not say what it treats or how to dose it. FDA rules exempt reminder ads from the brief summary, but not for drugs whose labeling carries a boxed warning, except price-only ads.

Do pharma companies have to monitor comments?

They must promptly review adverse drug experience information from any source, and a comment can contain it. Most companies set up daily monitoring and a route to the safety team before opening comments.

Do paid influencers need to follow FDA rules?

Plan for it. A post paid for by the manufacturer is made on its behalf, so it needs the same review as the brand's own content, plus a clear disclosure of the payment under the FTC's Endorsement Guides.

Has FDA finalised its social media guidance?

The 2014 draft on character space limits and the 2024 revised draft on misinformation are both drafts. Read them as FDA's current thinking and check for updates before each campaign.

When a patient asks an assistant about a condition

People now ask ChatGPT, Gemini or Perplexity things like "what are the treatment options for psoriasis" before they ask a doctor. The answer can name medicines and cite patient forums, health publishers and news, and the brand's own careful social content may play no part in it. Medical and regulatory teams should know what those answers say, because a patient may arrive at the appointment with them. AI Knows Us records what the major assistants say when people ask about a condition or a treatment, and which sources each answer cites.